Villingen-Schwenningen, 15 May 2015: NEXUS AG, specialized in hospital software, was able to increase sales by 22.4 % and its result before taxes and interest (EBIT) by 17.3 % in the first quarter 2015. As a result, the long-term and sustainable positive development of sales and earnings of the NEXUS Group could be continued.
Sales increased by approx. 22.4 % from KEUR 18,596 (Q1 2014) to KEUR 22,767 in the first quarter 2015. In the Healthcare Software Division, sales increased by 27.1 % and reached KEUR 21,159 (Q1 2014: KEUR 16,652). The Healthcare Service Division recorded sales of KEUR 1,608 in the first quarter 2015 after KEUR 1,944 (Q1 2014) and consequently 17.3 % less than in the previous year. The international share of to¬tal business volume was 51.6 % in the first quarter (Q1 2014: 45.9 %) and amounted to KEUR 11,752 follow¬ing KEUR 8,542 in the previous year. The sales of the subsidiary NEXUS / NEDERLAND consolidated for the first time are included in the figures. The development of the Swiss franc also had a positive effect on sales in the amount of KEUR 999.
Earnings after interest and taxes (EBIT) in the amount of EUR 2,126 improved compared to the same period last year by 17.3 % (Q1 2014: KEUR 1,812). The EBIT A improved by 42.1 % from KEUR 2,790 (Q1 2014) to KEUR 3,964. The EBITDA increased by 25.2 % to KEUR 4,332 (Q1 2014: KEUR 3,460) during the reporting period. The consolidated surplus amounted to KEUR 2,087 for the first quarter 2015 following KEUR 1,806 (Q1 2014) and consequently increased by approx. 15.6 %.
The cash flow in the first quarter developed especially strongly. The cash flow from current business trans¬actions reached KEUR 11,870 and consequently considerably surpassed the high value of the previous year of KEUR 8,164 (+45.4 %).
Earnings per share also developed positively and amounted to EUR 0.14 (Q1 2014: EUR 0.13).
NEXUS AG has equity capital amounting to KEUR 88,439 (31 Dec. 2014: KEUR 75,812). As a result, NEXUS AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.
